NBIX
Neurocrine Biosciences, Inc. · Healthcare · Biotechnology
Señales de momentum (gestores comparables): amplitud de titulares 0.0% · flujo de acciones -1.3% · nuevas posiciones netas -4.5% · fórmula
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q3 2025
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | -1 | 642.22K | $90.01M | n/a | −3 |
| Q2 2026 | 152 | 0 | 75.82M | $12.77B | +5 | −6 |
| Q1 2026 | 156 | 0 | 77.10M | $10.14B | +6 | −7 |
| Q4 2025 | 155 | 0 | 77.25M | $10.95B | +1 | n/a |
| Q3 2025 | 22 | 0 | 59.57M | $8.36B | +1 | −2 |
| Q2 2025 | 20 | -1 | 49.44M | $6.21B | +2 | −3 |
| Q1 2025 | 18 | 0 | 22.97M | $2.54B | +1 | −1 |
| Q4 2024 | 18 | 0 | 21.48M | $2.93B | +1 | −1 |
| Q3 2024 | 17 | 0 | 13.43M | $1.55B | n/a | n/a |
| Q2 2024 | 17 | n/a | 11.91M | $1.64B | n/a | n/a |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (pasivo) | 12.71M | -1.9% | $1.78B | 0.0% | ▼ Trim | 2 | SEC ↗ ×21 |
| 2 | The Vanguard Group ✦ (pasivo) | 9.71M | -1.0% | $1.36B | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | JPMorgan Chase ✦ | 9.46M | n/a | $1.33B | 0.0% | n/c | 1 | SEC ↗ ×30 |
| 4 | Dodge & Cox ✦ | 5.56M | -0.2% | $780.04M | 0.4% | ▼ Trim | 6 | SEC ↗ |
| 5 | State Street Global Advisors ✦ (pasivo) | 4.35M | -2.7% | $610.16M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 2.87M | -7.1% | $402.43M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 7 | AQR Capital Management ✦ | 2.77M | +83.7% | $388.44M | 0.2% | ▲ Add | 6 | SEC ↗ ×7 |
| 8 | Renaissance Technologies ✦ | 2.42M | +2.2% | $339.48M | 0.4% | ▲ Add | 6 | SEC ↗ |
| 9 | Geode Capital Management ✦ (pasivo) | 2.02M | +3.4% | $283.50M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | Morgan Stanley ✦ | 1.83M | n/a | $256.47M | 0.0% | n/c | 1 | SEC ↗ ×17 |
| 11 | Wellington Management ✦ | 1.81M | -10.7% | $254.34M | 0.0% | ▼ Trim | 6 | SEC ↗ ×6 |
| 12 | Millennium Management ✦ | 977.21K | -18.2% | $137.18M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 793.24K | -61.3% | $111.35M | 0.1% | ▼ Trim | 6 | SEC ↗ ×2 |
| 14 | Goldman Sachs Group ✦ | 609.61K | n/a | $85.58M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 15 | PRIMECAP Management ✦ | 512.26K | -2.2% | $71.91M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 16 | Arrowstreet Capital ✦ | 411.66K | +228.9% | $57.79M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 17 | Two Sigma Investments ✦ | 347.56K | Nuevo | $48.79M | 0.1% | New | 1 | SEC ↗ |
| 18 | Gotham Asset Management ✦ | 136.35K | +49.6% | $19.14M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 19 | Marshall Wace ✦ | 97.29K | +133.6% | $13.66M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 20 | Fisher Asset Management ✦ | 94.80K | +8.3% | $13.31M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 21 | Fidelity (FMR) ✦ | 72.34K | -71.6% | $10.16M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 22 | Bridgewater Associates ✦ | 23.04K | +157.6% | $3.23M | 0.0% | ▲ Add | 6 | SEC ↗ |
"Their weight" = la participación de la posición en el valor de renta variable 13F reportado por ese manager: la medida de convicción. ✦ = manager curado.
Nuevos compradores
| Two Sigma Investments | $48.79M | 0.1% |
Posición cerrada
| Norges Bank | $122.28M | era 0.0% |
| Adage Capital Partners | $42.93M | era 0.1% |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 690 tenedores, 94.09M acciones, $12.08B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué más suelen tener los titulares rastreados de este valor: recuentos de titularidad compartida, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer · 826 acc. · $130,051
Officer · 2.31K acc. · $363,285
Officer · 2.15K acc. · $333,030
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología